Pertuzumab (Perjeta®) in neoadjuvant HER2 positive breast cancer

Assessment Status Assessment Process Complete
Drug Pertuzumab
Brand Perjeta®
Indication Is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.
Assessment Process
Rapid review commissioned 10/08/2015
Rapid review completed 01/09/2015
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full submission received from Applicant 17/11/2015
NCPE assessment completed 10/05/2016
NCPE assessment outcome Reimbursement not Recommended

Technical Summary

Following NCPE assessment of the Applicant’s submission, cost effectiveness of pertuzumab (Perjeta®) (in combination with trastuzumab and chemotherapy) for this indication has not been demonstrated. Therefore it is not recommended for reimbursement.

Reimbursement was approved for this indication following confidential price negotiations July 2020.